Immunotherapy plus chemotherapy for advanced gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (ipilimumab and sintilimab) plus chemotherapy to shrink gastric cancer that cannot be surgically removed. The goal is to make the cancer small enough for surgery and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with gastric or gastroesophageal junction cancer that cannot be surgically removed
- Cancer must have a specific marker (PDL1 CPS≥1) detected on biopsy
- Age 18–80 years with good overall health (ECOG score 0–1)
- Never had previous gastric surgery, chemotherapy, radiation, or immunotherapy
- Blood counts, liver function, and kidney function must be adequate
- No active infections, uncontrolled heart disease, or other serious medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug sintilimab to two different chemotherapy combinations before surgery can help people with locally advanced gastric cancer that has a specific genetic feature (dMMR). You would receive treatment before surgery to shrink the tumor, then have surgery to remove it.
This trial tests a new treatment combination for locally advanced stomach cancer. First, you would receive a heated chemotherapy wash inside your abdomen (HIPEC). Then you would get the immunotherapy drug serplulimab plus standard chemotherapy (SOX or XELOX) before surgery, to shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
Hear when a new Locally Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.